The International Association for the Study of Pain has designated 2013--2014 as the Global Year Against Orofacial Pain; therefore, it was timely that the Canadian Orofacial Pain Team Workshop was held in Montreal (Quebec) on November 21 and 22, 2013. The workshop was sponsored by the Orofacial Pain Team Workshop, the Network for Canadian Oral Health Research, and the Institute of Musculoskeletal Health and Arthritis of the Canadian Institutes of Health Research. A multidisciplinary group of clinical, research and knowledge-transfer experts gathered from across Canada and abroad to pursue two aims: to identify new pathways for innovative diagnosis and management of chronic orofacial pain states; and to identify opportunities for further collaborative orofacial pain research and education in Canada.

Three main topics were presented, followed by panel discussions. The outcome was three sets of proposals for promising directions in chronic orofacial pain research, with the aim of improving the quality of life of orofacial pain patients through better diagnosis and management. Each set of proposals was presented to the full workshop so that overlapping opportunities could be identified and ideas for new research collaborations generated.

TOPIC 1: BIOPSYCHOSOCIAL MARKERS AND PAIN SIGNATURES FOR CHRONIC OROFACIAL PAIN
===============================================================================

F Chouchou, T Dao, G Deluca-Canto, L Diatchenko, R Dubner, JP Goulet, N Huynh, G Lavigne, P Rainville, P Schweinhardt, Z Seltzer, P Svensson, A Velly
-----------------------------------------------------------------------------------------------------------------------------------------------------

A number of issues were raised about the different types of chronic pain that can persist in the head, face and neck. First, there is currently no consensus on the types of chronic orofacial pain under the major pain classifications established by the American Academy of Orofacial Pain, the International Association for the Study of Pain and the International Headache Society. Different definitions and terminologies are used, and they are different with regard to their explanations of causes (etiology), descriptions of signs and symptoms, and diagnostic criteria. This reflects the lack of knowledge and the need for future studies along the lines of what was performed for temporomandibular disorders (TMD) in the recently updated Research Diagnostic Criteria for TMD ([@b1-prm-20-7],[@b2-prm-20-7]). Among the many types of orofacial pain, TMDs are the most common ([@b3-prm-20-7],[@b4-prm-20-7]). TMDs involve pain in the joint that connects the two jaw bones and muscles that move the jaw ([@b1-prm-20-7],[@b5-prm-20-7]). Second, although certain risk factors for chronic orofacial pain have been identified, the underlying mechanisms remain largely unclear. Third, chronic orofacial pain is frequently accompanied by comorbid pain conditions elsewhere in the body, as well as general health, psychosocial, sleep or motor disturbances, which complicate diagnosis and management. Fourth, reports of acute and chronic orofacial pain prevalence range widely, from 3% to 12%. Fifth, pain per se is also difficult to quantify and is commonly only assessed by the patient's own subjective report. Sixth, there is insufficient evidence for the power of current approaches to predict patients' response to pain medications. Consequently, clinicians must prescribe pain medications based on their own experience or using trial and error.

On the other hand, several tests are now available to help assess orofacial pain. These include psychosocial questionnaires and psycho-physiological tests such as qualitative sensory testing, which can be performed chairside, and quantitative sensory testing (QST), which is usually performed under experimental conditions but is applied in some clinics. QST approaches have been developed to test somatosensory functions such as heat and cold sensitivity, mechanical detection threshold, mechanical pain threshold, mechanical pain sensitivity, wind-up ratio, vibration detection threshold and pressure pain threshold. Both types of tools are considered to be reasonably reliable and sensitive, and are used to identify biomarkers of chronic orofacial pain, to help uncover the underlying mechanisms of pain, and to measure acute postoperative or chronic pain and response to treatment ([@b6-prm-20-7]--[@b9-prm-20-7]). Brain imaging is also a powerful tool to better understand sensory and emotional mechanisms of pain, the role of pain expectation on placebo analgesia and the endophenotype of pain ([@b10-prm-20-7],[@b11-prm-20-7]).

A biomarker is a naturally occurring molecule, gene or characteristic that can be used to identify and better understand a disease or disorder. Several biomarkers can be used to better understand pain in general and orofacial pain in particular. For example, electroencephalography (EEG) signals can be used to record the brain's electrical activity when pain occurs. They are particularly useful in surgery and postsurgical situations and for children, the elderly and patients who cannot communicate for any reason. However, some types of EEG signals correspond with patient-reported pain better than others. For example, EEG gamma oscillations have been proposed as potential pain biomarkers. They are also useful for predicting subjective pain intensity and for indicating pain experienced during the various states of consciousness, such as those associated with anesthesia, psychoactive medication and sleep ([@b12-prm-20-7]--[@b14-prm-20-7]). The pain-reward mechanism, placebos and sleep studies are research avenues that may help to better characterize pain biomarkers in relation to risk factors and comorbidities ([@b15-prm-20-7]--[@b18-prm-20-7]). Brain imaging methods include a number of proven bio-marker approaches that can identify sensory and emotional responses to pain in specific brain structures. New imaging methods are being applied in both mechanistic and treatment efficacy studies (eg, sensory perception, placebo, medication and cognitive behavioural studies) ([@b19-prm-20-7]--[@b21-prm-20-7]). Major advancements have been made in understanding TMD pain. For example, medical history (ie, comorbidities) has been linked to sensation related to pain pressure tests as a clinical biomarker, and genes have been linked to psychosocial factors ([@b22-prm-20-7]). The identification of genotype (DNA sequence) and epigenetic features (non-DNA changes that could have occurred over time and in interactions with behaviour) are paths to be further investigated; such research needs to be performed, given the complexity of pain and the considerable variability in its expression in pain patients, as recently reported by a group of experts in pain research and genetics ([@b10-prm-20-7],[@b23-prm-20-7],[@b24-prm-20-7]). Other promising biomarkers are being explored, including cytokines, which are essentially hormonal regulators that are released through a complex chain of neural events and that come into play during infections, immune responses, inflammation and trauma ([@b25-prm-20-7]). Cytochromes, which are naturally occurring enzymes, are also biomarkers worth exploring.

Another conclusion of the first workshop session was that more collaborative work, rather than single-laboratory studies, is needed to identify promising biomarkers and phenotypes and assess associations with other factors such as stress, psychological and environmental influences, and the impact of comorbidities. In addition, better cytokine, genetic and, eventually, epigenetic testing methods are required to gain a deeper understanding of the neurological interactions as well as the role of motor and sleep function in the genesis and/or persistence of chronic orofacial pain. An exemplary model has been provided by the Oral Pain: Prospective Evaluation and Risk Assessment (OPPERA) project on TMD, a multicentre prospective clinical study launched by the United States National Institutes of Health to assess the role of psychosocial, clinical, psychophysiological and genetic variables ([@b22-prm-20-7],[@b26-prm-20-7]).

These various issues prompted a workshop panel discussion and led to the following research recommendations, with a focus on chronic neuropathic orofacial pain conditions such as burning mouth, post-traumatic or postsurgical pain and trigeminal neuralgia (intense facial pain due to nerve damage) ([@b27-prm-20-7]--[@b29-prm-20-7]).

Panel 1: Research recommendations concerning biopsychosocial markers of chronic orofacial pain
----------------------------------------------------------------------------------------------

The workshop participants had identified the need for further studies on potential biomarkers, using questionnaires on health and mood, qualitative sensory testing and QST, as well as genetic markers to improve disease diagnosis and to measure changes in orofacial diseases and pain. The panel discussed these points and first considered that a useful biomarker should be variable in the population and it should show moderate heritability. This raised some critical questions about how to assess biomarkers for chronic orofacial pain: How can representative samples of individuals with chronic orofacial pain be obtained and tested? Which chronic orofacial pain conditions should be considered? Which chronic orofacial pain traits should be assessed? These basic questions need to be answered before chronic orofacial pain can be properly studied and treated.

Further issues concern the appropriate phenotypes (genetically based characteristics and traits that interact with the environment) to examine, such as endophenotypes, which are intermediate phenotypes. To date, there is no consensus on the most informative phenotypes to consider. Uncertainty regarding the risk factors (eg, social, cultural, psychological, genetic, epigenetic) and mechanisms involved in chronic orofacial pain was mentioned.

Of the neuropathic orofacial pain conditions, research into post-traumatic neuropathic pain (PTNP) appears to be one of the most promising directions, as described below in the recommended research directions ([@b30-prm-20-7]--[@b32-prm-20-7]).

There is a wealth of phenomic and genetic data available, much of it generated by animal studies, but more information is needed to fully understand the dynamics of chronic neuropathic orofacial pain. For instance, although pain sensitivity varies among individuals, it is known that TMD is associated with different types of psychological stress. Association gene studies can identify how genetic makeup (in terms of architecture, locus, pathways and targets) is associated with pain and its characteristics.

The panel proposed the following specific recommendations: Develop a prospective study in a new cohort of patients who have sustained orofacial trauma, and follow these patients to identify those who transition to chronic PTNP.Administer psychological, personality, clinical and psychophysical tests to patients in this proposed study, also taking into consideration cultural differences among these patients.Collect saliva and blood to extract genomic DNA, non-nucleotide markers (epigenetic changes over time), peptides and protein expression, etc, as potential markers of the main pain outcomes and endophenotypes for PTNP. Inclusion of inflammation-immune biomarkers is also necessary.Conduct brain imaging experiments in a subset of the patients to assess the biological and emotional dimensions of pain.Data collection from a cross-Canada cohort is expected to last between three and five years.Study animal models of PTNP to identify analogous biomarkers and underlying mechanisms of PTNP.

TOPIC 2: MISUSE OF ANALGESIC WITH A FOCUS ON OPIOID PAIN MEDICATIONS FOR MANAGING CHRONIC OROFACIAL PAIN
========================================================================================================

B Cairns, K Craig, JP Goulet, A Kolta, D Lam, G Lavigne, M Lynch, J O'Keefe, S Potvin, N Rei, A Samaha, E Whitney
-----------------------------------------------------------------------------------------------------------------

For years, clinicians have expressed concern about prescribing opioids due to the risks of misuse, abuse and addiction. However, orofacial pain cannot be managed without such risks ([@b33-prm-20-7]). Recently, clinicians, the media and politicians are taking this concern more seriously ([@b34-prm-20-7]). In Ontario alone, from 2006 to 2008, 58% of drug-related deaths (n=1,359) were associated with opioids ([@b35-prm-20-7]). This is a highly sensitive issue for Canadian clinicians who are managing acute and chronic pain. They must balance the risks against the patient's rights, expectations of pain relief and effectiveness of the treatment ([@b36-prm-20-7],[@b37-prm-20-7]).

But how serious is the opioid problem? According to the Canadian Alcohol and Other Drug Use Monitoring Survey, one in five (19%) Canadians with chronic pain reported using opioids, and 4.8% of these acknowledged nonmedical prescription opioid use (NMPOU) ([@b38-prm-20-7],[@b39-prm-20-7]). NMPOU refers to the use of opioids by individuals who acknowledge using pain relievers more than they were instructed to, obtaining a pain reliever from family or friend, or from any source without a prescription (ie, diversion of prescribed medication), or using a pain reliever to get high. Nevertheless, the single leading reason for using opioids in \>50% of individuals who engage in NMPOU appears to be pain relief ([@b39-prm-20-7],[@b40-prm-20-7]). This raises a crucial question: are we managing pain with the most effective medications and tools?

Opioids are used medically to obtain relief from intense pain and to avoid the consequences of pain on daily functioning, mood changes and suicidal ideation. These are risks that need to be weighed against the risks of misuse and addiction. Currently, 8% of fibromyalgia patients are reported to be at risk for suicide, and this risk is five times higher in chronic pain patients with a history of illicit drug use ([@b41-prm-20-7],[@b42-prm-20-7]).

As the number of opioid prescriptions rises, opioid addiction and misuse rates are rising in parallel ([@b34-prm-20-7],[@b43-prm-20-7]). Although clear guidelines are available for opioid use to manage chronic noncancer pain (<http://nationalpaincentre.mcmaster.ca/opioid/>), the problem remains critical, and we need to reconsider our approach ([@b37-prm-20-7],[@b44-prm-20-7]). First, the workshop participants were concerned about the fact that patients with chronic pain and who use opioids regularly are frequently stigmatized as addicts. For most, this is the only way to obtain pain relief and maintain a minimal quality of life. It is, therefore, critical to understand the difference between legitimate use and dependence or addiction. Physical dependence is normal and temporary, although it is associated with withdrawal. Addiction, on the other hand, is a primary neuropsychiatric disorder involving compulsive, uncontrolled drug-seeking and drug-taking behaviours. Opioids may also trigger a dopamine-related reward process in the brain, changes that appear to be very long-lived ([@b45-prm-20-7],[@b46-prm-20-7]). The net effect is a reward-based synaptic process in the brain that influences and possibly alters many cognitive functions, including learning, memory, judgment, prediction, reward and motivation processes ([@b47-prm-20-7],[@b48-prm-20-7]). The pursuit of natural rewards may turn into a compulsive pursuit of drugs, which is what clinicians want to prevent.

Mental health status and the risk for opioid misuse or addiction are critical issues that must be considered before prescribing opioids for chronic use ([@b44-prm-20-7],[@b49-prm-20-7],[@b50-prm-20-7]). Interestingly, patients with schizophrenia do not appear to suffer from chronic pain as much as the rest of the population. They feel the pain, but do not appear to care. This may be due to alterations in their pain-processing mechanisms resulting from a change in the complex interplay between the brain's excitatory and inhibitory systems. Schizophrenics can exhibit higher dopamine activity, which makes them less sensitive to nociceptive pain (typically the acute pain resulting from injury, infection or inflammation) ([@b51-prm-20-7],[@b52-prm-20-7]). However, the safety of opioid use by patients with mental health problems remains a challenging issue ([@b44-prm-20-7],[@b49-prm-20-7]).

Sometimes regular use of any type of analgesic, including opioids, will actually worsen the problem. Headaches may progress from occasional to regular, and constipation is an unpleasant adverse effect. Furthermore, regular opioid use may also trigger hyperalgesia in some susceptible individuals: they become more sensitive to pain or feel pain more intensely. Hyperalgesia is a complex physiological reaction that may lead to requests for higher doses, known as opioid overuse pain syndrome. These individuals should be taken off the medication for an appropriate length of time ([@b53-prm-20-7],[@b54-prm-20-7]).

The long-term benefits and safety of opioid use for chronic non-cancer pain remains an open issue ([@b34-prm-20-7]). Moreover, only 15% to 25% of patients significantly benefit from opioids after three years of regular use ([@b55-prm-20-7]). According to the opioid guidelines for long-term use for noncancer pain, patients should be \>30 years of age and experiencing moderate to severe pain that compromises their functioning. They should be capable of using the medication in the prescribed manner. Furthermore, they should be unable to take other effective medications, for whatever reason ([@b37-prm-20-7]).

When is it appropriate to prescribe opiates for chronic orofacial pain, and how should medication use be monitored? Again, the major medical organizations have not reached a consensus on guidelines for specific and safe treatments without the risks of misuse or addiction. The Canadian Guidelines for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain and more recent concerns were highlighted during the workshop ([@b36-prm-20-7],[@b37-prm-20-7],[@b44-prm-20-7],[@b56-prm-20-7]). The recommendations include taking a thorough patient history and screening for potential misuse. Medication effectiveness should be monitored and informed consent for treatment obtained. Work-related risks may also need to be assessed, eg, for commercial drivers and pilots ([@b57-prm-20-7]). Morphine equivalent doses \>200 mg per day appear to be associated with an increased risk for death if abused and, thus, this dose is recommended as the upper limit for treatment of chronic noncancer pain. Furthermore, because morphine and other opioid analgesics may also exacerbate breathing disturbances during sleep in vulnerable patients, the lowest possible dose is recommended in these patients ([@b58-prm-20-7],[@b59-prm-20-7]). Elderly patients should be tapered off benzodiazepines because the combination of opioid analgesics and benzodiazepines is likely to cause excessive sedation and breathing disturbances in this population. Initial opioid doses should be small, and different opioids should be tried to find the best one. In 1986, the WHO suggested a stepwise approach, also known as the analgesic pain pyramid ([@b60-prm-20-7]). Effectiveness, adverse events and aberrant behaviour should be noted. The medication may need to be given in another dose, switched to another type or terminated. If medications appear to be misused, patients can be prescribed methadone or buprenorphine, or given limited prescriptions and patient education with monitoring approaches can be used to minimize drug abuse and resale (diversion). Urine testing is the most effective monitoring method, but the use of such tests is controversial due to Canadian ethics and confidentially issues ([@b56-prm-20-7]).

Use of tamper-resistant formulations is an approach to prevent misuse/abuse of opioids under study by governmental agencies in Canada. However, more research is needed to confirm its effectiveness for daily use by patients, and other strategies need to be developed in parallel to prevent abusers from switching to other drugs such as heroin ([@b61-prm-20-7]--[@b63-prm-20-7]). The obligation to protect the population against drug misuse and abuse has to be balanced with the human right of patients experiencing severe chronic pain to obtain pain relief ([@b64-prm-20-7]).

Dentists who prescribe opioids to chronic orofacial pain patients to manage acute or chronic pain must also become involved in preventing opioid misuse and addiction ([@b33-prm-20-7]): To manage acute pain, the lowest-risk drugs should be prescribed first (eg, nonsteroidal anti-inflammatory analgesics such as acetylsalicylic acid, acetaminophen or ibubrofen). Opioid drugs should be prescribed only for severe or chronic pain after all other alternatives have been tried (eg, cognitive behavioural therapy, antiepileptic medications such as pregabalin, or antidepressive medications such as amitriptyline or duloxetine). The analgesic pain pyramid paradigm needs to be taught and promoted in clinical practice ([@b60-prm-20-7]).Clinicians should prescribe the minimum number of pills needed to manage the pain, and include a renewable option. After oral surgery, between 10 and 40 doses are being prescribed, with a mean of 20. Generally, a considerable proportion of prescribed pain pills are leftovers, and we do not know what patients do with them ([@b33-prm-20-7],[@b65-prm-20-7]).By reducing the number of prescribed pills, including a repeat prescription option when permissible and getting pharmacists more involved in renewal procedures, the risk of leftover pills can be reduced. Leftover pills are a major cause of misuse and distraction (use of medications for purposes other than pain relief) ([@b33-prm-20-7]). Pharmacists are key partners in managing repeat prescriptions. For instance, they can limit the number of pills over the first few days to help prevent the risks associated with leftovers. They could also offer return of unused medication to the pharmacy for proper destruction. Clinicians who prescribe opioids should be aware that they need to be available to answer pharmacists' questions. Otherwise, the safety chain to prevent misuse is broken ([@b66-prm-20-7]).

Screening patients for their risk of opioid misuse, abuse or addiction according to the Canadian and United States guidelines can dramatically reduce opioid misuse ([@b37-prm-20-7],[@b44-prm-20-7],[@b56-prm-20-7]). Clinicians should also be alert for certain behaviours exhibited by their patients, such as 'doctor shopping', frequently lost prescriptions, repeated requests for prescriptions, stealing or borrowing drugs, forging prescriptions or resisting changes to their medication even when there are adverse side effects. Identified predictors of misuse are a history of taking multiple substances, psychiatric disorders, alcohol or cocaine abuse, a family history of substance abuse, young age, criminal past, high-risk environment, social and/or employment problems, thrill-seeking behaviour, heavy smoking, and severe depression or anxiety. Which individuals are least at risk? They include older, generally compliant, stable, thoughtful, responsible and easy-going types.

Among the proposed assessment strategies are patients' self-report clinical questionnaires and interviews, and clinicians' checklists. However, the most effective strategy is a urine test, if the patient agrees (see the Guidelines, <http://nationalpaincentre.mcmaster.ca/opioid/>). Patients should be monitored regularly, and some provinces and states have prescription monitoring programs to help with this. It is important to keep in mind that only a small percentage of chronic pain patients will misuse or become addicted to opioid pain medications. As mentioned above, clinicians should be trained in the choice of pain medication, dosages, number of pills, reduction of leftover pills and follow-up methods. They should inform their patients about alternative pain management methods, the need to avoid giving pills to family members or friends, to not mix drugs with alcohol and to avoid using other medications not recommended by the clinician, including illegal drugs. These approaches are instrumental for preventing misuse and eventual addiction ([@b56-prm-20-7],[@b67-prm-20-7]).

When investigating or treating pain, we should not overlook social and psychological aspects. Pain is the result of complex interactions among many factors, including individual biology, the personal experience of pain and environmental influences. Pain and opioid analgesic addiction cannot be considered outside of this vast biopsychosocial context. Besides treating individual patients with empathy and awareness, dentists and physicians should not be ruled by either opiophilia or opiophobia.

Participants in the workshop panel discussed all of these issues and proposed recommendations for future research, as presented below.

Panel 2: Research recommendations related to opioid misuse for managing chronic orofacial pain
----------------------------------------------------------------------------------------------

The panel discussed the workshop presentations and identified some key issues that remain to be clarified. It is unclear how often Canadian family dentists prescribe opioid analgesics to treat moderate to severe chronic orofacial pain.There is little evidence to support the use of opioid analgesics in chronic orofacial pain.The use of opioid analgesics for chronic orofacial pain that has not responded adequately to all other treatments may be considered, but only for the subgroup of patients with persistent orofacial pain who have not responded to other surgical, pharmacological or psychological approaches (eg, post-traumatic pain, postsurgical or endodontic pain and, more rarely, musculoskeletal pain).The decrease in opioid efficacy and safety over time as well as the risk for sleep breathing abnormalities in susceptible patients also remain critical issues to consider.The panel developed the following specific recommendations: Conduct prospective studies to assess the best and safest management of acute orofacial pain to prevent chronic pain.Include in such studies measures of pain, including brain imaging and genetic biomarkers, as well as psychosocial risk factors for misuse and addiction.Include measures over six-month periods to determine the prevalence of persistent postoperative pain and post-traumatic pain and the relationship to chronic opioid use.Test screening algorithms, prevention protocols (lowest dose and number of pills; prescription renewal to avoid unused opioid pills), and education programs for clinicians and patients in terms of their effectiveness in dental practice and their impacts on the risk of misuse and addiction.

TOPIC 3: COMPLEMENTARY AND ALTERNATIVE MEDICINE, TOPICAL AGENTS AND THE ROLE OF STRESS IN CHRONIC OROFACIAL PAIN
================================================================================================================

L Avivi-Arber, K Blanchard, N Rei, J Sawynok, P Schweinhardt, B Sessle, P Svensson, V Singh, N Thie, M Ware, A Woda
-------------------------------------------------------------------------------------------------------------------

Patients use complementary alternative medicine (CAM) for both 'push' and 'pull' reasons. Push reasons include dissatisfaction with conventional medicine due to side effects, long waiting lists, ineffective treatments and lack of time. People may also reject science and technology in general, or the so-called 'establishment', or they may be desperate because they are not being listened to or are not obtaining the expected pain relief. Pull reasons include a belief in the safety and effectiveness of natural, holistic, noninvasive treatments that are in line with their personal philosophy. Patients also believed that they have active control over their treatment, and they can spend more time with practitioners. Treatments range from traditional Chinese medicine and meditation to biofeedback, physical therapy, massage, chiropractic therapy, acupuncture and electric fields, to name only a few. In general, they are 'lower-tech' and higher-touch than conventional treatments. CAM content is barely present in the dental education curriculum. This is not surprising because CAM is rarely taught in clinical medicine ([@b68-prm-20-7],[@b69-prm-20-7]).

Not all CAM approaches are without risks, however. Natural products, such as tea tree oil and black willow bark, are used to treat pain, but they come with certain safety issues, such as potential drug-herb interactions and lack of standardization. The use of an evidence-based approach is mandatory in all health disciplines and, in recent years, CAM research has made significant progress in providing more information on efficacy and safety, partly due to more open-minded government attitudes (<http://nccam.nih.gov>). In addition, some patients who use CAM may not seek conventional medical help for more serious conditions that require diagnosis and more aggressive medical treatment (eg, oncology). Patients should be made to understand that they need to report their use of CAM because some treatments may have negative interactions with pharmacological agents (eg, those used for anxiety and in oncology) ([@b70-prm-20-7],[@b71-prm-20-7]). It should also be mandatory for studies investigating CAMs to report any adverse effects, a condition that is rarely met but is becoming more standard ([@b72-prm-20-7],[@b73-prm-20-7]). Although CAM is frequently used to treat general chronic pain, there is only limited evidence for its effectiveness in treating most types of chronic orofacial pain ([@b74-prm-20-7]).

In the case of acupuncture, there is an ongoing debate regarding whether acupuncture really 'works' (ie, the endogenous analgesic systems are activated) or whether patients feel better because of the 'needling effect'. In other words, acupuncture analgesia may involve a type of active placebo effect, as occurs in other therapeutic treatments and in relation to the patient's beliefs ([@b75-prm-20-7]). There is some evidence supporting the use of acupuncture for managing TMD pain ([@b76-prm-20-7]).

Traditional Qigong is an ancient Chinese practice involving movements, postures, breathing exercises and meditation. It has been reported to significantly and sustainably improve a wide range of conditions, including chronic orofacial pain, food allergies, asthma, sleep disorders, carpel tunnel syndrome and migraines, among others. It appears to be more effective when practiced regularly; thus, highly motivated individuals would benefit most from it ([@b77-prm-20-7]). However, rigorous trials combining quantitative and qualitative approaches are needed to provide hard evidence on the benefits and the best approaches for delivery ([@b73-prm-20-7],[@b78-prm-20-7],[@b79-prm-20-7]).

Biofeedback, which involves the use of electrical stimulation to inhibit muscle activity, appears to have a positive effect on sleep bruxism (tooth grinding) and some chronic pain conditions (TMD, headache, fibromyalgia); however, paradoxically, it does not appear to significantly reduce pain intensity ([@b80-prm-20-7]). It has been suggested that a combination of biofeedback and cognitive behavioural therapy would be more effective ([@b81-prm-20-7]). More information is needed through long-term follow-up studies involving larger patient samples.

Some CAM procedures may also relieve pain by reducing stress. It is known that chronic orofacial pain as well as many other conditions, such as chronic fatigue syndrome and fibromyalgia, are stress-related (stress was also identified as a possible biomarker of chronic orofacial pain in topic 1) ([@b82-prm-20-7]). Abnormal or sustained exposure to stress causes an abnormal response to stress, such that the stress system is in a state of permanent failure. Instead of the normal short-alarm reaction to daily stresses, which sends extra oxygen and glucose to the body so it can cope with emergencies, fibromyalgia patients experience a 'longer' type of stress response in which they fail to receive that 'extra fuel'. These patients may first need to perform more endurance exercise (ie, low-intensity, long-duration exercise) and progressively add resistance exercise (ie, short duration of repeated, more intense effort), to reeducate their stress response system (A Woda, unpublished observations). Pain management exercise programs provide a promising treatment avenue, if performed safely. Although there is little supporting evidence -- and the little that is available is considered to be low quality -- this avenue merits further investigation ([@b83-prm-20-7]--[@b85-prm-20-7]).

Recently, an alternative to conventional medication routes has been introduced, namely the use of topical agents such as ointments, mouth rinses, powders and sprays for orofacial pain conditions ([@b86-prm-20-7], [@b87-prm-20-7]). They are applied as local anesthetics, antidepressants, anticonvulsants, anti-inflammatories and more. They have no or only minimal side effects and they generally do not interact with other drugs. They are particularly beneficial for patients who cannot ingest certain medications and will certainly be useful in an aging population. For the most effective treatment, it is important to find a pharmacist who can properly compound the agent. Burning mouth syndrome was proposed to be sufficiently prevalent as to merit further study, and topical clonazepam was mentioned as a treatment that is not widely known to many practitioners yet may be useful for a number of patients. Promising avenues to pursue include the use of topical agents to relieve burning mouth pain and other types of neuropathic orofacial pain. Agents such as clonidine (an alternative to clonazepam, with a safer addiction profile) could be investigated through randomized controlled trials ([@b88-prm-20-7],[@b89-prm-20-7]).

Participants in the workshop panel discussed all of these issues and proposed recommendations for future research, as outlined below.

Panel 3: Research recommendations related to CAM, topical agents and the role of stress in chronic orofacial pain
-----------------------------------------------------------------------------------------------------------------

The first research direction proposed by the panel was to clarify the difference between CAM and the use of topicals (ie, topical analgesics). The point was raised that they form an unlikely pair because CAM involves untested and unaccepted therapies, whereas topical agents are pharmaceuticals, with a different delivery system. It was decided that they should be considered as independent entities for the purposes of chronic orofacial pain management because they appear to act through different mechanisms and because topical agents fall into the category of standardized pharmacotherapeutic interventions.

Burning mouth syndrome and neuropathic orofacial pain were identified as common disorders that are, nevertheless, rarely encountered by general practitioners treating chronic orofacial pain. In addition, and even when referred to a specialized practitioner, the management strategies developed to date to help these patients are often ineffective. The panel proposed the following research recommendations: Establish awareness and education groups, with an emphasis on reviewing the current knowledge and formulating guidelines to assist clinicians in decision making with respect to burning mouth syndrome.Develop a multicentre study of treatments for burning mouth syndrome (eg, capsaicin and lidocaine compared with clonidine versus placebo rinse). Thus, capsaicin-lidocaine treatment could be investigated parallel to clonidine treatment.Use larger samples in efficacy or effectiveness trials to assess the benefits and risks of CAM and the use of topical medications as alternatives to systemic medication.Conduct CAM studies using animal models of chronic orofacial pain to better understand the mechanisms of action of CAM, and promote translational research to enhance CAM acceptance for treatment of pain and associated factors such as mood alterations, sleep disturbances and stress-response disturbances for improvements in quality of life.

MAIN CONCLUSIONS AND FUTURE DIRECTIONS FOR CHRONIC OROFACIAL PAIN RESEARCH AND MANAGEMENT
=========================================================================================

Because almost 20% of Canadians experience chronic pain and 8% have chronic orofacial pain, these patients need help to prevent psychological and societal dysfunction. In addition, medication misuse is a recognized problem in Canada that may lead to addiction and suicide. It was clear to the workshop participants of the need to devote greater attention to chronic orofacial pain to improve the quality of life of chronic orofacial pain patients.

It was also clear from the workshop discussions and recommendations that more research is needed to identify biomarkers of chronic orofacial pain (as revealed through the use of approaches such as brain imaging and genetic characterization), and to clarify societal, cultural and environmental interactions, using analyses of large population data sets.

Furthermore, it was recommended to develop pharmacological, psychological-behavioural and CAM treatments and to monitor their long-term efficacy and safety, and determine the underlying mechanisms in animal and human experimental models.

More comprehensive and overarching explorations (multidisciplinary approaches) are needed to obtain a more complete picture of what happens when pain occurs or persists ([Table 1](#t1-prm-20-7){ref-type="table"}).
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Suggested directions for future national and international collaborative research in chronic orofacial pain

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Develop collaborations among major pain associationsReach a consensus on classification (taxonomy) and harmonization with newer international research diagnostic criteriaEstablish standard diagnostic testsIntegrate brain, genetic and immune biomarker research findings and technological advances within a more comprehensive diagnostic approachConduct interdisciplinary longitudinal studies to assess behavioural, psychological, societal, environmental, epigenetic (non-DNA changes) and genetic (DNA changes) risk factors and disease progressionConduct prospective studies and develop evidence-based and tailored treatments for medical, dental and complementary and alternative medicine applications and practiceInitiate comparative effectiveness studies (ie, real-world settings) versus classical efficacy randomized clinical trials (ie, too often conducted in overly controlled or selective conditions for regulatory agency needs)Establish reliable treatment efficacy and efficiency outcomes by using valid monitoring testsUse animal models to identify chronic orofacial pain biomarkers and complimentary alternative medicine mechanismsSet clear guidelines or best practices guidance, in collaboration with professional organizations and government agencies, on opioid use for safe chronic orofacial pain management (dose, number of pills, unused pill risk)Partner with health professional colleges, governmental agencies, pharmacists and family physicians to develop strategies to prevent opioid misuse and abusePromote the use of evidence-based complementary and alternative medicine approaches to chronic orofacial pain managementDevelop a strategic communication plan to update clinicians and educate the public on the best and safest treatments for chronic orofacial pain
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: Workshop speakers and debate participants are listed as co-authors under each topic title
